ZYME
NASDAQ
$23.76
Zymeworks BC Inc (ZYME)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $39.33 (+65.53%)
Market Cap
$1.80B
Free Cash Flow Yield
-4.27%
Beta (5Y)
0.83
Price Chart
Valuation
Market Cap$1.80B
Forward P/E24.21
P/S22.33
P/B11.09
Profitability
Total Revenue (TTM)$81M
Gross Profit (TTM)-$54M
EBITDA-$110M
Profit Margin-126.3%
Operating Margin-1957%
EPS-$1.39
Financial Health
Free Cash Flow Yield-4.27%
Growth & Risk
Beta (5Y)0.83
Sharpe Ratio1.11